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INTRODUCTION
Heart failure (HF) represents a major epidemic with high morbidity and mortality rates, imposing
a significant burden on healthcare systems worldwide (Savarese and Lund, 2017). HF has long
been distinguished by ejection fraction (EF) into two types—HF with reduced ejection fraction
(HFrEF), for which EF is below 40%, and HF with preserved ejection fraction (HFpEF), for which
EF is above 50% and, according to the 2016 European Society of Cardiology (ESC) Guidelines
(Ponikowski et al., 2016), accompanies (1) an elevated level of natriuretic peptides (BNP > 35
pg/ml and/or NT-proBNP> 125 pg/mL) and (2) the presence of either structural heart disease (left
ventricular hypertrophy and/or left atrial enlargement) or diastolic dysfunction. HFrEF andHFpEF
were initially considered to be binary opposing entities at two ends of the same spectrum. However,
whilst several studies have demonstrated the efficacy of drug therapies in improving quality-of-life
and long-term clinical outcomes in HFrEF patients, such pharmacological approaches have often
failed to yield similar observable benefits in HFpEF cohorts. As such, the current paradigm follows
that the pathogenesis underscoring the development and progression of HFrEF and HFpEF are
distinct. In more recent developments, the 2016 ESC Guidelines (Ponikowski et al., 2016) also
proposed a third class of HF–HF with mid-range ejection fraction (HFmrEF), for which EF is
between 40 and 49%, and accompanies the same two aforementioned components of HFpEF.
Investigations into this newly defined group of HF patients have yielded contradicting results:
whilst some findings have demonstrated an overlap between HFmrEF and the other two classes,
others have shown no such association. As a result, a greater understanding of the underlying
mechanistic differences between the HF groups, particularly pertaining to HFpEF and HFmrEF,
is still needed in order to ensure successful diagnoses and holistic treatment provision.
The proposed mechanism for HFrEF is generally well-understood, in which adverse myocardial
remodeling, resulting from cardiomyocyte death (Gonzalez et al., 2011) secondary to an inciting
stimulus, such as viral myocarditis, myocardial infarction, or drug-induced cardiomyopathy
(Bloom et al., 2017), leads to systolic dysfunction (Figure 1A). The same however cannot be said for
HFpEF, which is instead associated with a more heterogeneous pathophysiology (Kao et al., 2015).
Epidemiological studies have illustrated a comparatively stronger relationship between HFpEF
(as opposed to HFrEF) with multiple cardiac and non-cardiac co-morbidities, including but not
limited to type 2 diabetes mellitus (T2DM), arterial hypertension, renal failure, obesity, and atrial
fibrillation (Elguindy and Yacoub, 2012). This evidently diverse clinical phenotype has elicited
much debate regarding the precise mechanisms involved in the development of HFpEF.
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SYSTEMIC
PROINFLAMMATORY HYPOTHESIS
One potential hypothesis suggests that HFpEF is simply the
additive outcome of the many associated co-morbidities acting
synergistically (Kao et al., 2015). Paulus et al. proposes a
mechanism that lends credence to this notion by indicating that
the concurrent existence of conditions such as T2DM, obesity,
arterial hypertension, and pulmonary disease is responsible
for inducing a systemic proinflammatory state (Figure 1B),
characterized by elevated levels of tumor necrosis factor (TNF)-
α, interleukin (IL)-6, and IL-1ß, amongst many others (Van
Linthout and Tschöpe, 2017). Such cytokines in turn initiate a
series of signaling events that ultimately culminate in reduced
endothelial nitric oxide (NO) production and diminished activity
of the cyclic guanosine phosphate-protein kinase G (cGMP-
PKG) pathway in cardiomyocytes. This cascade of reactions
eventually results in cardiomyocyte stiffness coupled with
myocardial collagen deposition and fibrosis, therein leading
to the development of hypertrophy, diastolic dysfunction and
HFpEF (Paulus and Tschöpe, 2013). This theory has been
supported not only by various animal models demonstrating the
protective role of NO-cGMP-PKG signaling against myocardial
hypertrophy (Calderone et al., 1998) and stiffness (Matsubara
et al., 1998), but also by certain investigations showing the efficacy
of anti-inflammatory agents (statins) in reducing mortality in
HFpEF patients (Liu et al., 2014; Alehagen et al., 2015; Marume
et al., 2019). Moreover, it must be noted that the aforementioned
systemic proinflammatory state is, in fact, also involved in the
pathogenesis of HFrEF, whereby in addition to cardiomyocyte
death secondary to an inciting stimulus, elevated levels of IL-
6 and TNF-α also mediate a reduction in NO-cGMP-PKG
signaling that contributes to myocardial dysfunction (Paulus
and Tschöpe, 2013). However, despite the apparent importance
of inflammation in the pathogenesis of HFpEF (and HFrEF),
a significant proportion of conducted clinical trials have also
demonstrated the ineffectiveness of anti-inflammatory statins
as well as vasoprotective ACE inhibitors (Fu et al., 2012) and
angiotensin II receptor antagonists (Yusuf et al., 2003) in HFpEF
cohorts, thereby somewhat diminishing the credibility of the
systemic proinflammatory hypothesis.
MULTI-ORGAN DISEASE HYPOTHESIS
An alternative theory is the belief that HFpEF, rather than
being a single disease, instead results from the interaction of
multiple underlying physiological ailments. These include not
only a reduction in diastolic function and cardiac reserves
but also impairments in the renal and pulmonary systems
(Borlaug, 2014), all of which collectively show significant
inter-individual variations (Roh et al., 2017). The severity
of these conditions is age-dependent (Parikh et al., 2018),
and frailty (Tse et al., 2018; Zhang et al., 2018), a syndrome
resulting from an age-related reduction in physiological
function, itself has been linked with adverse outcomes in
HF (Figure 1C). All in all, this notion of a differential
phenotypic expression resulting from a complex interplay
of multiple comorbidities is well-accepted, and likely accounts
for the failure of conventional pharmacological therapies used
in HFrEF to yield the same beneficial outcomes in HFpEF.
Nonetheless, recent efforts have been made to construct
animal models that closely mimic HFpEF phenotype. Obesity
as well as salt-driven hypertensive models have both been
used to accurately study respiratory muscle weakness and
associated exercise intolerance in HFpEF. Seiler et al. describes
salt-loaded hypertensive HFpEF rats with diaphragmatic
muscle alterations secondary to elevated plasma levels of
inflammatory cytokines (TNF-α, IL-1β, etc.), consistent with
the systemic proinflammatory hypothesis (Seiler et al., 2016).
Moreover, models of renal insufficiency-driven hypertension
have also shown to present with LV hypertrophy and poor
LV relaxation, reflective of the diastolic dysfunction related
to HFpEF (Munagala et al., 2005). However, as previously
stated, HFpEF is characterized by multiple comorbidities that
interact to produce to the final phenotype. This cannot be
replicated by animal models, which normally elucidate the
mechanistic role of only one particular comorbidity (e.g.,
arterial hypertension, obesity, renal insufficiency, etc.) in the
development of HFpEF. Whilst this approach allows for an
understanding of the relationship between each individual
comorbidity and HFpEF (Valero-Muñoz et al., 2017), it will
likely serve to benefit only a subset of patients for whom the
investigated comorbidity is the predominant factor contributing
to disease pathogenesis.
LV DYSSYNCHRONY
Both the systemic proinflammatory state andmulti-organ disease
hypotheses encompass the role of left ventricular diastolic
dysfunction (LVDD) in HFpEF development. LVDD has long
been considered the major causative factor of HFpEF; however,
many previous trials aiming to reduce long-term mortality
by enhancing diastolic function, namely by improving LV
relaxation and/or halting the progression of LV hypertrophy
through the antagonism of the renin-angiotensin-aldosterone
system, have failed to report favorable outcomes (Cleland et al.,
2006; Massie et al., 2008). Such findings have warranted and
fueled the search for other contributing mechanisms central
to the pathogenesis of HFpEF for prospective targeting in
the clinical setting. One such alternative that is becoming
increasingly investigated is LV dyssynchrony (Figure 1D), which
stems from the regional variations in the rate of contraction
and relaxation of fibers in the myocardium, in turn resulting
in impaired cardiac performance (Lee et al., 2011). Although
it is said to exist in ∼30–40% of HFrEF patients (Liu et al.,
2018), LV dyssynchrony and its severity have also now been
associated with the development of HFpEF (Lee et al., 2011;
Santos et al., 2014). Lee et al. showcased not only the
existence of systolic and diastolic dyssynchrony at rest in
an HFpEF cohort relative to normal controls but also the
subsequent aggravation of dyssynchrony when HFpEF patients
were exposed to dobutamine-induced hemodynamic stress (Lee
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FIGURE 1 | A schematic diagram demonstrating the current theories of underlying pathophysiology in different classes of heart failure. (A) Pathophysiology of HFrEF.
(B) Pathophysiology of HFpEF. (C) Role of Frailty in HFpEF. (D) Role of LV Dyssynchrony in HF.
et al., 2010). Moreover, Morris et al. demonstrated that the
development of LV dyssynchrony is, in fact, associated with
subendocardial fibrosis that occurs secondary to a vast majority
of comorbidities typically accompanying the HFpEF phenotype
(Morris et al., 2012). Such dyssynchrony has been implicated in
the development of systolic dysfunction in HFpEF patients, in
which delayed myocardial activation diminishes pump efficiency
(Cheng et al., 2009). In addition, it has also been postulated
that asynchronous LV contraction leads to temporal variability in
LV relaxation, particularly during early diastole, wherein certain
myocardial fibers relax later than others (Bonow et al., 1988).
This subsequently decreases diastolic function, presenting as a
reduction in passive LV filling and an increase in LV filling
pressures (Morris et al., 2012). All in all, the dynamicity of
mechanical dyssynchrony, along with the resulting systolic and
diastolic dysfunction, are clearly important to the manifestation
of HFpEF, and in turn provide reason as to why therapies
that focus solely on the improvement of diastolic function
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without any regard for LV dyssynchrony have failed to yield
fruitful outcomes.
MECHANISMS OF HFmrEF
In contrast to HFpEF and HFrEF, there is a relative paucity
in literature discussing the phenotype of HFmrEF, and as
such, this condition has often been referred to as the “middle
child” in the HF family. The pathophysiology of HFmrEF,
which accounts for ∼10–20% of all HF patients (Nadar and
Tariq, 2018), is largely unknown. Current evidence indicates
that HFmrEF may be the outcome of a progressive worsening
in LV function in HFpEF patients, most notably observed
in those with concomitant coronary artery disease, which is
associated with a deterioration in LVEF (Lam and Solomon,
2014). An alternative possibility is that HFmrEF results
from an improved systolic function in patients with HFrEF.
This particular subset of HFmrEF is clinically relevant, as
recovered systolic function in HF patients has been linked
with reduced mortality and a more favorable long-term
prognosis (Nadruz et al., 2016). Regardless of its pathway
of development, many studies have presented HFmrEF as
an intermediate phenotype with clinical characteristics and
outcomes in between the other two classes of HF, albeit
more closely related to HFrEF (He et al., 2009; Rickenbacher
et al., 2017; Lund et al., 2018). Although such findings of
an intermediate clinical profile would support the notion of
HFmrEF as a distinct condition—a subset of neither HFpEF
nor HFrEF—additional studies are still required for this to
be confirmed and for the pathogenesis of HFmrEF to be
further elucidated.
CARDIAC IMAGING, BIOMARKERS, AND
NETWORK ANALYSIS
The heterogeneity of HF has necessitated the use of various
techniques in cardiac imaging for diagnosis and prognosis
assessment, namely transthoracic echocardiography (TTE),
cardiac computerized tomography, and magnetic resonance
imaging (Butler, 2007; Inamdar and Inamdar, 2016). Moreover,
three-dimensional speckle tracking in echocardiography, a
relatively recent development, has also proven to be an accurate,
relatively efficient method for assessing LV function in research,
thereby warranting its more frequent implementation in the
clinical setting for the evaluation of HF (Luo et al., 2014;
Xu et al., 2014). However, in addition to the aforementioned
cardiac imaging methods, numerous biomarkers related to
the pathological processes of HF, such as inflammation
(Petersen and Felker, 2006; Bozkurt et al., 2010), myocardial
mechanical stress, and fibrosis (Ahmad et al., 2014; López
et al., 2015; Li et al., 2018), cardio-renal dysfunction (Senthong
et al., 2017), and even the ovarian cancer marker cancer
antigen-125 (Cheung et al., 2018), have been identified
and investigated. Such biomarker studies perhaps provide
some of the most important avenues through which the
diversity of HF can be further understood. Recently, network
analysis has been implemented as a tool to study different
multi-marker interactions for the purpose of obtaining a
more comprehensive overview of the distinct pathogenesis
of the three classes of HF. Thus, far, this summative, all-
encompassing approach has somewhat unsurprisingly revealed
multiple shared protein-protein based relationships among
HFpEF, HFmrEF, and HFrEF. However, findings have also
indicated varying biomarker signatures within the different
HF groups. Most notably, HFpEF pathways were uniquely
associated with markers of inflammation whilst HFrEF pathways
were enriched with markers of cardiac stretch and cellular
proliferation, both showing minimal overlapping with HFmrEF
(Tromp et al., 2017, 2018). The identification of such specific
biochemical interactions not only emphasizes the unique
pathophysiology of the three types of HF but also provides
insight into potential drug targets, and in turn, suggests
the need for dynamic multi-marker screening for optimal
risk stratification.
PHENOMAPPING
In addition to network analysis, another method that has
more recently been implemented to assess the underlying
heterogeneity in HF, amongst various other diseases, is
“phenomapping,” which involves machine-based learning to
analyze large sums of phenotypic data in order to categorize
patients into distinct subgroups based on a select number of
clinical features (Katz et al., 2017). Katz et al. demonstrated
the use of this technique to successfully identify distinct
subgroups of hypertensive patients with a predisposition to
HFpEF development owing to the presence of abnormal
cardiac mechanical properties (Katz et al., 2017). Similarly,
Shah et al. also used machine learning to stratify an HFpEF
cohort according to a series of unrelated clinical phenotypic
features found in the domains of patient demographics, physical
characteristics, as well as laboratory, ECG and echocardiography
parameters. This classification yielded three distinct “pheno-
groups” of HFpEF patients, all of whom presented with
variable baseline data. Pheno-group #1 was characterized by
low levels of brain natriuretic peptide (BNP), which is typically
associated with obesity. A lack of BNP promotes renal sodium
and water retention, culminating in an increase in plasma
volume, preload, and LV hypertrophy. As a result, such a
“BNP deficiency syndrome” could likely serve as a possible
explanation for the underlying etiology of diastolic dysfunction
and subsequent HFpEF in this particular subset of patients.
Pheno-group #2 encompassed a phenotype of cardio-metabolic
disease, which can disturb myocardial electrical and mechanical
function, whilst pheno-group #3 consisted of patients with
the highest BNP levels, but concurrent right ventricular and
renal dysfunction that predisposed to the highest risk of
hospitalization and mortality (Shah et al., 2015; Shah, 2017).
With the findings of these investigations, it is evident that
phenomapping can serve as a tool to circumvent the problem
of heterogeneity in HF by categorizing patients into distinct,
clinically relevant clusters. The identification of such subgroups
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would subsequently allow for the development of patient-
specific, targeted therapies that could potentially improve long-
term prognosis.
CONCLUSION
The three classes of HF are all characterized by distinct
pathophysiological processes, which in turn contribute to the
heterogeneity in the expressed phenotype. Whilst there is
currently less unknown about HFrEF, literature pertaining to
HFpEF and the newly classified HFmrEF still incites many
questions with respect to pathogenesis and optimal therapeutic
strategies. Specifically, more prospective studies, as opposed to
cross-sectional studies, that follow HFpEF and HFmrEF patients
for a lengthy time period are required to assess whether or
not the development of HF is truly, in fact, a continuum that
progresses from HFpEF through to HFmrEF and eventually
HFrEF. Overall, the diversity in the observed clinical features,
namely of HFpEF and HFmrEF, poses challenges to the creation
of a universal treatment regimen that will fit all patients. As such,
future management of these two conditions, in particular, will
likely necessitate the implementation of a patient-specificmethod
that targets unique metabolic derangements present in distinct
patient subgroups. Although tools such as network analysis and
machine-based learning that attempt to collate and find links
between available data have proven to yield informative results, a
greater understanding of the underlying mechanisms involved in
the development of HFpEF and HFmrEF is still required before
this individualistic approach can be employed holistically in the
clinical setting.
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